TNDM, US8753722037

Mizuho cuts target for Tandem Diabetes Care stock from USD 20.00 to USD 18.00

Published on 10/18/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mizuho cut its target from USD 20.00 to USD 18.00 on October 13, 2026. Tandem Diabetes Care stock posted USD 254.56 million in second-quarter sales.

Analyst target and earnings date

Mizuho lowered its Tandem Diabetes Care target from USD 20.00 to USD 18.00 on October 13, 2026.
Second-quarter revenue reached USD 254.56 million after USD 247.22 million in the first quarter of 2026.
Tandem Diabetes Care will report third-quarter 2026 results on November 5, 2026.

TNDM, US8753722037, Illustration mit AI erstellt.

Tandem Diabetes Care stock is facing a lower analyst valuation after Mizuho cut its price target from USD 20.00 to USD 18.00 on October 13, 2026. As Markets Insider reported, analyst Anthony Petrone retained a Neutral rating while citing expected procedure-volume pressure from changes affecting the Affordable Care Act and Medicaid.

Target cut meets improving sales

The operating picture contains a stronger sales trend than the revised target alone suggests. Tandem generated USD 247.22 million in revenue in the first quarter of 2026 and USD 254.56 million in the second quarter, a 2.97 percent sequential increase.

Second-quarter gross profit reached USD 144.78 million, producing a 57.00 percent gross margin, compared with 55.00 percent in the first quarter. Benzinga reported that management maintained 2026 sales guidance of USD 1.065 billion to USD 1.085 billion and gross margin guidance of 56.00 percent to 57.00 percent.

Three dated developments

On July 1, 2026, Tandem announced compatibility between its t:slim X2 pump and Abbott's FreeStyle Libre 3 Plus sensor in five international markets, according to Tandem Diabetes Care. On September 28, 2026, the company expanded Tandem Mobi availability to 12 international markets, also listed in its release archive.

On October 13, 2026, Mizuho reduced its target to USD 18.00 from USD 20.00 while keeping a Neutral rating, according to Markets Insider.

When are results due

The next scheduled company event is the third-quarter 2026 earnings release on November 5, 2026. Tandem Diabetes Care said the results will be released after the market close, followed by a conference call.

Execution faces a valuation test

The coming report will put the USD 1.065 billion to USD 1.085 billion annual sales outlook against the pressure highlighted by Mizuho. Revenue growth and the 57.00 percent second-quarter gross margin are the clearest operating measures for judging whether the lower target reflects caution or a weaker trajectory.

The further course of trading is shown by the continuously updated real-time quote of Tandem Diabetes Care stock.